Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gsalpha |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. L. Omara-Opyene et al., Lab Invest., 2004 Jul; 84(7):894-907 | |||
Gsalpha-QL |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | K. A. Iczkowski et al., Anticancer Res, Jul 2006; 26: 2863 - 2872 | Link | ||
HEC-1A |
Human endometrial carcinoma cell line | ATCC HTB-112 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | H. Kiaris et al., PNAS, Aug 2003; 100: 9512 - 9517 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. Kobe de Oliveira et al., J. Biol. Chem., May 2007; 282: 13656 - 13663 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | A. Raturi et al., J. Cell Biol., Aug 2016; 214, 433 - 444 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Benincá et al., J. Med. Genet., 2021, 58: 155–167, doi:10.1136/jmedgenet-2020-106861 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | V. Mikat et al., RNA, Dec 2007; 13: 2341 - 2347 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | D.W. Chen et al., In: C. Boon, J. Wijnholds (eds) Retinal Gene Therapy. Methods in Molecular Biology, 2018, 1715, Humana Press, NY | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S. de la Fuente et al., Biochem. J., 2014, 458: 33-40, doi:10.1042/BJ20131025 | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., J. Lipid Res., Nov 2008; 49: 2312 - 2322 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. M. Nalaskowski et al., J. Biol. Chem., Feb 2011; 286: 4500 - 4510 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | K. Wethmar et al., Oncogene, 2016, 35,1736-1742; doi:10.1038/onc.2015.233 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S.-B. M. Varda et al., 2012, WO 2007/043049 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. C. Mayer et al., J. Immunol., Oct 2013; 191: 3594 - 3604 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | V. Pfaumann et al., Cellular Microbiology, (2015, 17(4): 579-594; doi:10.1111/cmi.12386 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Rampoldi et al., Hum. Mol. Genet., Dec 2003; 12: 3369 - 3384 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. Stretton et al., Biochem. J., Sep 2015; 470: 207 - 221 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/siRNA) | Metafectene | publication | X. M. M. Weyel, Dissertation, 2018, Goethe- Universität in Frankfurt am Main | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Berro et al., J. Virol., Apr 2006; 80: 3189 - 3204 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Vay et al., J. Physiol., 2007, 580.1, 39-49 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T.-H. Kang et al., Mol. Cell. Biol., Dec 2007; 27: 8533 - 8546 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Mahmoodi et al., IET Nanobiotechnol., 2017, 11 (8): 995-1004 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Pagano et al., 2014, US 8,778,905 | Link |